

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1. Name and Address of Company

Izotropic Corporation (the “**Company**”)
15718 39A Avenue
Surrey, BC V3Z 0L1

Item 2. Date of Material Change

September 14, 2018

Item 3. News Release

The News Release dated September 14, 2018 was disseminated by Stockwatch and Market News on September 14, 2018.

Item 4. Summary of Material Change

The Company announced, further to its news release of August 13, 2018, that it has closed the non-brokered private placement financing (the “**Offering**”). Pursuant to the Offering, the Company sold 500,000 units (each, a “**Unit**”) at a price of \$0.20 per Unit for gross proceeds of \$100,000. Each Unit was comprised of one common share and one share purchase warrant (each, a “**Warrant**”), with each Warrant entitling the holder to purchase one additional share at a price of \$0.40 per share until September 14, 2019. The use of proceeds of the Offering will be used for general working capital purposes.

All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

None of the securities issued in the Offering have been registered under the *United States Securities Act of 1933*, as amended (the “**1933 Act**”), and none of them have been offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Item 5. Full Description of Material Change

5.1 Full Description of Material Change

See attached September 14, 2018 News Release.

5.2 Disclosure for Restructuring Transactions

Not Applicable.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not Applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

Please contact Robert Thast, Chief Executive Officer of the Company, at 604-542-9458.

Item 9. Date of Report

September 14, 2018

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

IZOTROPIC CORPORATION

IZOTROPIC CORPORATION ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT

VANCOUVER, BC – September 14, 2018 – **Izotropic Corporation** (“**Izotropic**” or the “**Company**”) (CSE: IZO) is pleased to announce, that further to its news release dated August 13, 2018, it has closed the non-brokered private placement financing (the “**Offering**”). Pursuant to the Offering, the Company sold 500,000 units (each, a “**Unit**”) at a price of \$0.20 per Unit for gross proceeds of \$100,000. Each Unit was comprised of one common share and one share purchase warrant (each, a “**Warrant**”), with each Warrant entitling the holder to purchase one additional share at a price of \$0.40 per share until September 14, 2019. The use of proceeds of the Offering will be used for general working capital purposes.

All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

None of the securities issued in the Offering have been registered under the *United States Securities Act of 1933*, as amended (the “**1933 Act**”), and none of them have been offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

About Izotropic

The Company is engaged in the development and commercialization of next generation 3-D breast CT imaging technology for early diagnosis of breast cancer, that improves patient comfort, provides a true 360-degree view acquisition and delivers high diagnostic accuracy.

ON BEHALF OF THE BOARD

“Robert Thast”

Robert Thast

Chief Executive Officer, Director
and Promoter

For further information, please contact:

Robert Thast
Telephone: 604.542.9458

Email: bthast@izocorp.com